Fishers, Ind. – City of Fishers representatives joined List Biotherapeutics, Inc. (List Bio), List Labs, and Genome & Company executives to break ground on List Bio’s new $125 million, 110,000 square foot contract manufacturing facility today. The facility, which spans 15 acres in the Fishers Life Science & Innovation Park, will be completed by the end of 2023.
List Bio parent company, Korean-based Genome & Company (KOSDAQ: 314130), invested in the firm’s sister company, List Labs, to expand its manufacturing capabilities to offer an end-to-end manufacturing solution from early-stage development to late-stage clinical trials and commercialization. The company plans to hire 210 employees in Fishers in the areas of biologics manufacturing and quality and regulatory compliance.
“Breaking ground on yet another headquarters at the Life Science & Innovation Park is a humbling moment,” said Fishers Mayor Scott Fadness. “Our vision to create a hub for biopharma and biotech is becoming a reality and we’re grateful that the teams at Genome and List Bio have entrusted Fishers to be their home, where they will impact lives all around the world.”
List Bio’s commitment to the City of Fishers is another example of how the community’s business, talent, and innovation climates are coming together to create an ideal landing spot for biotech and biopharma companies. The City of Fishers has had $750 million in investment from biotech and biopharma companies since 2020.